Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (366)	12/29/1997 11:58:00 AM
From: flickerful	Read Replies (1) \| Respond to of 756

his words tracked the release, with the small exception being what "tentative" means...i.e. ivax getting a step closer with tentative approval sounds positive near term by sin of omission.... it was odd hearing for the first time the words paxene, baker norton ( an ivax wholly owned subsidiary), and napro biotherapeutics all at once in this context. jackson, we have a slew of releases about drugs, and finally hear the dismaying eventuality of paxene...only to hear it spun . it must have created knee jerks somewhere, i wonder if napro has had any overflow interest due to the sound bites... later, randy